Author: O.A. Fedorova, Ph.D. honey. scientific Ukrainian Military Medical Academy
Currently, allergic diseases are satellites of civilization and have become a global medical and social problem. The prevalence of allergic diseases, such as seasonal and persistent allergic rhinitis, urticaria, atopic dermatitis, bronchial asthma, is constantly growing [14, 22]. According to WHO data, allergic diseases rank third among other diseases in terms of frequency; in different countries, from 10 to 30% of the population suffers from allergies [24]. In addition, annually in the world from 12.7 to 28.5% seek medical help for seasonal allergic reactions: acute rhinitis, conjunctivitis, urticaria. The prevalence of allergic dermatosis (atopic dermatitis, eczema, urticaria, allergic contact dermatitis) in the structure of allergic diseases, according to foreign studies, ranges from 7 to 73% [1, 5]. It is extremely important that various allergic diseases are associated with each other, complicating the patient’s condition. Yes, allergic rhinitis often accompanies bronchial asthma, contributes to the development of sinusitis, otitis media, respiratory infections. Therefore, the choice of rational pharmacotherapy for allergic diseases is timely and relevant [1, 4].
Cetirizine is the most effective and promising antihistamine in the treatment of most allergic diseases, with the use of which the largest number of clinical studies have been conducted. This drug is on the FDA’s List of Essential and Essential Drugs.
Indications for its use are: allergic rhinitis and conjunctivitis, urticaria and other dermatoses, manifested by itching and rash, including in children, starting from 6 months. For patients who respond poorly to the therapeutic effects of other antihistamines, cetirizine is desirable. The possibility of long-term use allows us to recommend the drug for the secondary prevention of allergic diseases and comorbidities [13].
The high efficacy and safety of cetirizine, confirmed by evidence-based medicine, allow it to be used in a wide clinical practice.
Rolinoz, Italian-made cetirizine, has been registered on the pharmaceutical market of Ukraine and has proven itself due to its optimal price-quality ratio. Rolinoz is available in 2 forms: oral drops of 10 mg of cetirizine dihydrochloride in 1 ml of solution (20 drops) in a 20 ml vial and tablets of 10 mg of cetirizine dihydrochloride, 20 tablets per pack.
Published in a journal «Therapia. Ukrainian Medical Bulletin» № 3 (118)’202017